Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

VOLUNTARY ANNOUNCEMENT

Received FDA Emergency Use Authorization for Use of cPass™ SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening

Reference is made to the announcements of GenScript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 8 November 2020.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 5 February 2021 (New York time), GenScript USA Inc. ("**GS USA**"), a direct wholly-owned subsidiary of the Company, received authorization by the Center for Biologics Evaluation and Research (the "**CBER**") of the United States Food and Drug Administration (the "**FDA**") for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening. The cPass™ is the first FDA authorized test that specifically detects COVID-19 neutralizing antibodies without the use of live virus. Neutralizing antibodies block the ability of the virus to infect a cell and are widely recognized biomarkers of immunity.

Convalescent plasma from patients who have recovered from COVID-19 may contain antibodies that fight the virus and is often used as a transfusion treatment for patients hospitalized with COVID-19 to speed recovery. However, successful treatment with convalescent plasma has been variable and new tools are needed to help gauge its effectiveness.

The Group believes that the cPass™ is a valuable assay for identifying the functionality and level of antibodies in convalescent plasma prior to its use in treatment. It is believed that convalescent plasma that contains functionally active antibodies that neutralize COVID-19, rather than binding antibodies that do not block the virus, could be more effective than plasma with low or no neutralizing antibodies. This may potentially increase the effectiveness of convalescent plasma treatment, helping patients to recover more quickly.

The novel cPass™ test detects neutralizing antibodies in patient samples without the use of live virus. The conventional method to measure neutralizing antibodies in the patient samples requires the use of live cells and obtaining results takes multiple days and high safety level environment ("**BSL3**"). In contrast, the cPass™ kit utilizes pure proteins that can be performed in most standard laboratories with short turnaround time of approximately one hour.

The cPass™ kit is also CE (Conformite Europeenne) marked in Europe, and authorized by ANVISA in Brazil and Health Sciences Authorities in Singapore.

The Group remains committed to supporting the global healthcare community in combatting COVID-19 infections, with a broad portfolio of research and development tools and diagnostics, including the noval cPass™ kit.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 7 February 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*